Back لقاح السعال الديكي Arabic واکسن سیاهسرفه AZB পার্টুসিস টিকা Bengali/Bangla Pertussisimpfstoff German Εμβόλιο κοκκύτη Greek Vacuna contra la tos ferina Spanish واکسن سیاهسرفه Persian Vaccin contre la coqueluche French Vaksin batuk rejan ID Ọgwụ mgbochi patosis IG
 Pertussis vaccination is often administered via a combined DPT vaccine or, as shown here, a DTaP-IPV vaccine | |
| Vaccine description | |
|---|---|
| Target | Whooping cough |
| Vaccine type | Inactivated or subunit |
| Clinical data | |
| MedlinePlus | a682198 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Pertussis vaccine is a vaccine that protects against whooping cough (pertussis).[1][2] There are two main types: whole-cell vaccines and acellular vaccines.[1][2] The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.[1][3] The effectiveness of the vaccines appears to decrease by between 2 and 10% per year after vaccination with a more rapid decrease with the acellular vaccines.[1] The vaccine is only available in combination with tetanus and diphtheria vaccines.[1] Pertussis vaccine is estimated to have saved over 500,000 lives in 2002.[4]
Vaccinating the mother during pregnancy may protect the baby.[1] The World Health Organization and Centers for Disease Control and Prevention recommend all children be vaccinated for pertussis and that it be included in routine vaccinations.[1][5] Three doses starting at six weeks of age are typically recommended in young children.[1][2] Additional doses may be given to older children and adults.[1] This recommendation includes people who have HIV/AIDS.[1]
The acellular vaccines are more commonly used in the developed world due to fewer adverse effects.[1] Between 10 and 50% of people given the whole-cell vaccines develop redness at the injection site or fever.[1] Febrile seizures and long periods of crying occur in less than 1% of people.[1] With the acellular vaccines a brief period of non-serious swelling of the arm may occur.[1] Side effects with both types of vaccines, but especially the whole-cell vaccine, are less common the younger the child.[1] The whole-cell vaccines should not be used after seven years of age.[1] Serious long term neurological problems are not associated with either type.[1]
The pertussis vaccine was developed in 1926.[6] It is on the World Health Organization's List of Essential Medicines.[7]
- ^ a b c d e f g h i j k l m n o p q "Pertussis vaccines: WHO position paper – September 2015" (PDF). Relevé Épidémiologique Hebdomadaire. 90 (35): 433–458. August 2015. PMID 26320265. Archived from the original (PDF) on 4 March 2016.
- ^ a b c "The Immunological Basis for Immunization Series: Pertussis Vaccines". World Health Organization. Archived from the original on 23 March 2018. Retrieved 22 November 2017.
- ^ Zhang L, Prietsch SO, Axelsson I, Halperin SA (September 2014). "Acellular vaccines for preventing whooping cough in children". The Cochrane Database of Systematic Reviews. 2014 (9): CD001478. doi:10.1002/14651858.CD001478.pub6. PMC 9722541. PMID 25228233.
- ^ "Annex 6 whole cell pertussis" (PDF). World Health Organization. Archived (PDF) from the original on 24 March 2012. Retrieved 5 June 2011.
- ^ "Pertussis: Summary of Vaccine Recommendations". Centre for Disease Control and Prevention. Archived from the original on 29 June 2011. Retrieved 12 December 2015.
- ^ Macera C (2012). Introduction to Epidemiology: Distribution and Determinants of Disease. Nelson Education. p. 251. ISBN 9781285687148. Archived from the original on 8 September 2017.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search